METHYLDOPA ANHYDROUS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C10H13NO4
Molecular Weight	211.2145
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@](N)(CC1=CC(O)=C(O)C=C1)C(O)=O

InChI

InChIKey=CJCSPKMFHVPWAR-JTQLQIEISA-N

InChI=1S/C10H13NO4/c1-10(11,9(14)15)5-6-2-3-7(12)8(13)4-6/h2-4,12-13H,5,11H2,1H3,(H,14,15)/t10-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C10H13NO4
Molecular Weight	211.2145
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/13400s086lbl.pdfhttps://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f5f25053-a9f3-48b9-a412-078f5ee942fd&type=display
Curator's Comment: Description was created based on several sources, including

Methyldopate hydrochloride [levo-3-(3,4-dihydroxyphenyl)-2-methylalanine, ethyl ester hydrochloride] is the ethyl ester of methyldopa, supplied as the hydrochloride salt with a molecular weight of 275.73. Methyldopate hydrochloride is more soluble and stable in solution than methyldopa and is the preferred form for intravenous use. Methyldopate hydrochloride is an alpha adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
DOPA decarboxylase 15 Target ID: CHEMBL1843 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7136732	Inhibitor 8146	60.0 µM [IC50]
Adrenergic receptor alpha 64 Target ID: CHEMBL2095203 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f5f25053-a9f3-48b9-a412-078f5ee942fd&type=display	Agonist 2637
Adrenergic receptor alpha 64 Target ID: CHEMBL2094111 Sources: https://www.drugs.com/pro/methyldopa.html	Agonist 2637

Conditions

Condition	Modality	Highest Phase	Product
Hypertension 546 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/13400s086lbl.pdf	Primary	Approved 8307	ALDOMET Approved Use INDICATION AND USAGE: Hypertension. Launch Date -2.21961601E11
Preeclampsia 84 Sources: https://clinicaltrials.gov/ct2/show/NCT00117546	Primary	Phase IV 63	ALDOMET Approved Use INDICATION AND USAGE: Hypertension. Launch Date -2.21961601E11
Type 1 diabetes in DQ8 positive patients with residual beta cell function 4 Sources: http://reference.medscape.com/drug/aldomet-methyldopa-342385	Primary	Approved 8307	ALDOMET Approved Use INDICATION AND USAGE: Hypertension. Launch Date -2.21961601E11
Hypertension 546 Sources: https://www.drugs.com/pro/methyldopate.html	Primary	Approved 8307	Methyldopate hydrochloride Approved Use Hypertension, when parenteral medication is indicated. The treatment of hypertensive crises may be initiated with Methyldopate HCl Injection. Launch Date 8.1233281E11

C_max

Value	Dose	Co-administered	Analyte	Population
771.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21125810	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:		METHYLDOPA plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
4.54 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7047042	100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered:		METHYLDOPA plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
5352.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21125810	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:		METHYLDOPA plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.28 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7047042	100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered:		METHYLDOPA plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
12.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21125810	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:		METHYLDOPA plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
85% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7047042	100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered:		METHYLDOPA plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
2.5 g single, oral Dose: 2.5 g Route: oral Route: single Dose: 2.5 g Sources: https://pubmed.ncbi.nlm.nih.gov/7175995/	unknown, 19 n = 1 Health Status: unknown Age Group: 19 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/7175995/	Other AEs: Coma... Other AEs: Coma (grade 1) Sources: https://pubmed.ncbi.nlm.nih.gov/7175995/
2326 mg multiple, oral (mean) Recommended Dose: 2326 mg Route: oral Route: multiple Dose: 2326 mg Sources: https://pubmed.ncbi.nlm.nih.gov/20791420/	unhealthy, 36-68 n = 30 Health Status: unhealthy Condition: hypertension Age Group: 36-68 Sex: M+F Population Size: 30 Sources: https://pubmed.ncbi.nlm.nih.gov/20791420/	Disc. AE: Depression, Tiredness... AEs leading to discontinuation/dose reduction: Depression (2 patients) Tiredness (2 patients) Diarrhoea (1 patient) Rash (1 patient) Blackout (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/20791420/
250 mg 4 times / day multiple, oral Recommended Dose: 250 mg, 4 times / day Route: oral Route: multiple Dose: 250 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/14269222/	unhealthy n = 39 Health Status: unhealthy Condition: hypertension Sex: M+F Population Size: 39 Sources: https://pubmed.ncbi.nlm.nih.gov/14269222/	Other AEs: Somnolence, Dry mouth... Other AEs: Somnolence (15 patients) Dry mouth (12 patients) Malaise (6 patients) Constipation (5 patients) Anorexia (5 patients) Diarrhoea (3 patients) Depression (2 patients) Weight gain (2 patients) Mental confusion (1 patient) Postural hypotension (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/14269222/

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
			inhibitor 1570

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP450 65

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP450 65	substrate 3264 Sources: https://molpharm.aspetjournals.org/content/12/6/911 Page: abstract	likely

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1603	inhibitor 1584 Sources: https://www.scirp.org/pdf/JBiSE_2017112915210255.pdf Page: 10.0

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY560228	https://www.001chemical.com/chem/555-30-6
3B Scientific (Wuhan) Corp	3B2-0576	http://www.3bsc.com/index/pro_info.php?id=19932
AA Blocks	AA003RA4	http://www.aablocks.com/goods/Goods/detail?id=AA003RA4
AHH Chemical co.,ltd	API-1546	http://www.ahhchemical.com/product/API-1546.html
AK Scientific, Inc. (AKSCI)	H155	http://www.aksci.com/item_detail.php?cat=H155
Aaron Chemicals	AR003S1W	http://www.aaronchem.com/555-30-6
Achemtek	0104-003502	http://www.achemtek.com/41372-08-1
Achemtek	0104-006717	http://www.achemtek.com/555-30-6
Alfa Chemistry	88620-56-8	https://www.alfa-chemistry.com/cas_88620-56-8.htm
Angene	AGN-PC-0SJ63Q	http://www.angenechemical.com/productshow/AGN-PC-0SJ63Q.html
Anward	ANW-43632	http://www.anward.com/pro_result/24839
ApexBio Technology	B1787	http://www.apexbt.com/methyldopa.html
Ark Pharm	AK114179	http://www.arkpharminc.com/products/555-30-6.html
Aurora Fine Chemicals LLC	A17.866.470	http://online.aurorafinechemicals.com/info?ID=A17.866.470
BLD Pharm	BD21439	http://www.bldpharm.com/products/555-30-6.html
BioCrick	BCC4676	http://www.biocrick.com/Methyldopa-BCC4676.html
BioSynth	W-105555	https://www.biosynth.com/en/products/chemical-intermediates/basic-intermediates/products/W-105555.html
BioSynth	Q-201392	https://www.biosynth.com/en/products/life-science/other-biochemicals/products/Q-201392.html
Chem Scene	CS-2172	http://www.chemscene.com/555-30-6.html
ChemMol	30101538	http://www.chemmol.com/chemmol/30101538.html
ChemMol	30101832	http://www.chemmol.com/chemmol/30101832.html
ChemMol	99105050	http://www.chemmol.com/chemmol/99105050.html
ChemMol	99161463	http://www.chemmol.com/chemmol/99161463.html
Chemspace	CSSB00000008965	https://chem-space.com/CSSB00000008965
Clearsynth	CS-O-30639	http://www.clearsynth.com/en/CSO30639.html
DAOGE BIOPHARMA	DG21-11796	https://www.daogechem.com/product/555-30-6.html
DC Chemicals	DC32910	http://www.dcchemicals.com//product_show-Dopamet.html
Enamine	Z1565440340	https://www.enaminestore.com/catalog/Z1565440340
Hairui	HR122810	http://www.hairuichem.com/en/product/555-30-6.html
Hello Bio	HB1822	https://www.hellobio.com/l-alpha-methyldopa.html
Lab Network	LN00238713	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00238713
MedChem Express	HY-B0225	https://www.medchemexpress.com/l-_-_-_alpha_-methyldopa.html
Molcore	MC560228	https://www.molcore.com/product/555-30-6
Selleck Chemicals	S1642	http://www.selleckchem.com/products/Methyldopa(Aldomet).html
Sigma-Aldrich	M1500000_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/m1500000?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	Y0001083_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/y0001083?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1426002_USP	https://www.sigmaaldrich.com/catalog/product/usp/1426002?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S535194	http://www.smolecule.com/products/s535194
Smolecule	S773215	https://www.smolecule.com/products/s773215
TCI (Tokyo Chemical Industry)	D1817	http://www.tcichemicals.com/eshop/en/us/commodity/D1817/index.html
THE BioTek	bt-275646	https://www.thebiotek.com/product/inhibitors/bt-275646
Tocris	584	https://www.tocris.com/products/l-a-methyldopa_0584
TripleBond	CM0081	http://www.triplebond-canada.com/prod/1430/
VladaChem	VL272043-1G	https://www.vladachem.com/product.php?products=555-30-6
abcr GmbH	AB474211	http://www.abcr.com/shop/en/AB474211
eNovation Chemicals	K70850	https://www.enovationchem.com/ProductDetails.asp?ProductID=K70850
mcule	MCULE-8885874119	https://mcule.com/MCULE-8885874119/

PubMed

Title	Date	PubMed
Dementia induced by methyldopa with haloperidol.	1976 May 27	1264138
The effect of methyldopa on retinal artery circulation in pre-eclamptic gravidae.	2000 Jun	11005120
Treating hypertension in women of child-bearing age and during pregnancy.	2001	11368252
Ddc and amd sequences resolve phylogenetic relationships of Drosophila.	2001 Aug	11476641
Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase.	2001 Feb	11160877
Effect of phenobarbital and spironolactone treatment on the oxidative metabolism of antipyrine by rat liver microsomes.	2001 Jan-Feb	11785906
NHBPEP report on high blood pressure in pregnancy: a summary for family physicians.	2001 Jul 15	11476271
Pharmacokinetic and pharmacodynamic alterations of methyldopa in rats with aortic coarctation. A study using microdialysis.	2001 Nov	11712868
The effects of nitric oxide synthase inhibitors on the sedative effect of clonidine.	2001 Nov	11682401
Catechol-O-methyltransferase (COMT) genetic polymorphism in a Turkish population.	2001 Sep	11693181
Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs.	2002	12016548
Liddle syndrome in a newborn infant.	2002 Aug	12185466
Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice.	2002 Jan	11849292
C4 deficiency state in antiphospholipid antibody-related recurrent preeclampsia evolving into systemic lupus erythematosus.	2002 Jul	12111090
Analysis of L-dopa in human serum.	2002 Nov	12449374
Oral beta-blockers for mild to moderate hypertension during pregnancy.	2003	12917933
Determination of antioxidant activity of some drugs using high-pressure liquid chromatography.	2003	12785121
Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers.	2003	12464717
Methyldopa supplement for resistant essential hypertension: a prospective randomized placebo control crossover study.	2003 Dec	14971524
Replacement of antipsychotic and antiepileptic medication by L-alpha-methyldopa in a woman with velocardiofacial syndrome.	2003 Mar	12598825
Nocturnal sleep, daytime sleepiness, and quality of life in stable patients on hemodialysis.	2003 Nov 21	14633280
A survey of Canadian practitioners regarding the management of the hypertensive disorders of pregnancy.	2004	15117601
Pheochromocytoma during pregnancy: laparoscopic and conventional surgical treatment of two cases.	2004 Feb	15031775
Oral enalapril-hydrochlorothiazide-methyldopa as first line treatment for severe hypertension in Nigerians.	2004 Jan	14959973
Liquid chromatography-tandem mass spectrometry method for the determination of tranexamic acid in human plasma.	2004 Jun 15	15135101
[Centrally-acting antihypertensive drugs].	2004 Mar	15171442
[Hypertension in pregnancy].	2004 Mar	15171412
Drug-induced liver injury.	2004 Mar 1	14986274
Differential modulation by estrogen of alpha2-adrenergic and I1-imidazoline receptor-mediated hypotension in female rats.	2004 Oct	15145918
Treating high blood pressure in Africans with type 2 diabetes.	2004 Winter	15002939
Inadequate control of blood pressure in Nigerians with diabetes.	2004 Winter	15002927

Patents

Sample Use Guides

In Vivo Use Guide

Initial: 250 mg PO q8-12hr for 2 days, increase q2Days PRN Maintenance: 250-1000 mg/day divided q6-12hr PO, usually no more than 3 g/day IV (methyldopate): 250-1000 mg infusion over 30-60 minutes q6-8hr PRN; no more than 4 g/day

Route of Administration: Other

In Vitro Use Guide

Human uterine microvascular endothelial cells (UtMVEC) (PromoCell, Heidelberg, Germany) were cultured in EGM-2- MV medium (Lonza, Basel, Switzerland) until about 80% confluent. Cells from passage 4-8 were used in this study. Tissue culture plates (24-wells) were coated with undiluted Matrigel (300 μL/well; In Vitro Technologies, Noble Park, Vic., Australia) and polymerized for 30 minutes at 37°C. UtMVECs (100 000 cells/well) were seeded into each well and endothelial cell tubular networks formed within 4 hours of further incubation at 37°C. HTR-8/ SVneo cells (100 000 cells/well) were then added to each well with or without a low dose of TNF-α (0.5 ng/mL) together with methyldopa (5 μg/ mL), labetalol (0.5 μg/mL), hydralazine (10 μg/mL) or clonidine (1.0 μg/ mL) and co-cultured with the endothelial cellular networks. The control co-cultured cells had neither TNF-α nor medications added. After 24 hours of culture, the cells were retrieved from the cellular networks in Matrigel with Cell Recovery Solution (CRS) (In Vitro Technologies) for RNA extraction

Substance Class	Chemical Created by `admin` on `Fri Dec 16 18:47:42 UTC 2022` Edited by `admin` on `Fri Dec 16 18:47:42 UTC 2022`
Record UNII	M4R0H12F6M
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

METHYLDOPA ANHYDROUS

Common Name

English

J9.247I

Code

English

ANHYDROUS METHYLDOPA

Common Name

English

(-)-.ALPHA.-METHYLDOPA

Common Name

English

L-.ALPHA.-METHYL-3-(3,4)-DIHYDROXYPHENYLALANINE

Common Name

English

L-TYROSINE, 3-HYDROXY-.ALPHA.-METHYL-

Systematic Name

English

METHYLDOPA (LEVOROTATORY)

Common Name

English

BAYER-1440L

Code

English

(-)-METHYLDOPA

Systematic Name

English

ANHYDROUS METHYLDOPA [MART.]

Common Name

English

(-)-.ALPHA.-METHYL-3,4-DIHYDROXYPHENYLALANINE

Systematic Name

English

L-.ALPHA.-METHYLDOPA

Common Name

English

(2S)-2-AMINO-3-(3,4-DIHYDROXYPHENYL)-2-METHYLPROPANOIC ACID

Systematic Name

English

.ALPHA.-METHYL-L-DOPA

Brand Name

English

L-3-(3,4-DIHYDROXYPHENYL)-2-METHYLALANINE

Common Name

English

Methyldopa [WHO-DD]

Common Name

English

METHYL DOPA

Systematic Name

English

methyldopa [INN]

Common Name

English

METHYLDOPA [MI]

Common Name

English

LEDERDOPA

Brand Name

English

CARBIDOPA IMPURITY A [EP IMPURITY]

Common Name

English

METHYLDOPA [HSDB]

Common Name

English

NSC-169916

Code

English

METHYLDOPA, ANHYDROUS

Common Name

English

.ALPHA.-METHYL-L-3,4-DIHYDROXYPHENYLALANINE

Common Name

English

(S)-(-)-.ALPHA.-METHYLDOPA

Common Name

English

Classification Tree Code System Code

WHO-ATC

C02AB01